Shares of leading pharma major, Sun Pharma were trading 4.16 per cent lower at Rs 565 on BSE ahead of its second-quarter results scheduled to be released today. According to HDFC securities, the company's top-line growth is expected at 12 per cent YoY driven by a recovery in the US business post Halol resolution.

Also, sequential growth is expected to remain muted at 3-4 per cent.

Further, EBITDA margin improvement will remain muted because of increased spend on the speciality business. Meanwhile, shares of Sun Pharma opened at Rs 594.90 on BSE against its previous closing of Rs 589.55.